October 7, 2021
November 12, 2019
April 28, 2020
January 20, 2021
June 8, 2021
Washington, DC – June 8, 2021 – Friends of Cancer Research (Friends) is proud to announce the launch of Step 2 of the ctDNA for Monitoring Treatment Response (ctMoniTR) Project. This project aims to determine the extent to which changes in circulating tumor DNA (ctDNA) are an early indicator of response to therapy on a larger…
Learn MoreApril 12, 2021
Washington, DC – April 12, 2021 – Friends of Cancer Research would like to congratulate Dr. Patrizia Cavazzoni for being named the director of the Center for Drug Evaluation and Research (CDER) at the U.S. Food and Drug Administration (FDA). “The naming of Dr. Cavazzoni as director of CDER at FDA by Acting Commissioner Woodcock…
Learn MoreJanuary 20, 2021
Washington, DC – January 20, 2021 – Friends of Cancer Research (Friends) would like to applaud President Biden for selecting Dr. Janet Woodcock to serve as acting Commissioner of the U.S. Food and Drug Administration (FDA). We look forward to working with Dr. Woodcock in her new role as the acting lead at the FDA,…
Learn MoreDecember 22, 2020
Bipartisan MODERN Labeling Act Included Washington, DC – December 22, 2020 – Friends of Cancer Research (Friends) applauds the bipartisan work of the House and Senate to bolster the U.S. economy and support patients, physicians, and families during the COVID-19 pandemic. We would also like to acknowledge the strong bipartisan work of the Members and…
Learn MoreDecember 9, 2020
HRD Harmonization Project to Create Consistency in HRD Use Washington, DC – December 9, 2020 – Friends of Cancer Research (Friends) is proud to announce its latest research partnership, the HRD Harmonization Project. Homologous recombination deficiency, or HRD, is a complex biomarker that has much promise in identifying patients with certain cancers who are more…
Learn MoreDecember 2, 2020
Washington, DC – December 2, 2020 – Friends of Cancer Research (Friends) praises the scientific endeavor that has unfolded during the past months to discover a safe and effective vaccine against the novel coronavirus (COVID-19). It has been no small feat and could not have been achieved as quickly and safely as it has without…
Learn MoreOctober 19, 2020
On a daily basis, the U.S. Food and Drug Administration is responsible for making highly complex and consequential regulatory decisions. To meet this responsibility, the FDA must have a modern approach to the use of technology for its regulatory mission, such as the review of medical product applications and food safety, and other critical functions.…
Learn MoreSeptember 30, 2020
Real world evidence (RWE) is a pivotal tool in the battle against COVID-19. Real world data (RWD) are accumulating steadily from medical encounters, pharmacies, labs and other sources, awaiting exploration and evaluation. This information is critical to understanding how COVID-19 affects people, including what treatments they received, how well those treatments worked, etc. And as…
Learn MoreSeptember 30, 2020
Seven former commissioners of the US Food and Drug Administration (FDA) came together to call out the Trump administration for undercutting FDA’s credibility as the agency prepares to evaluate clinical trial data for vaccines against SARS-CoV-2, the virus causing the novel coronavirus pandemic. Their comments, made in an opinion column published 29 September in The Washington Post,…
Learn MoreSeptember 30, 2020
FDA biologics center director Peter Marks thanked seven former FDA chiefs for their recent op-ed in which they voice concern about the negative effects that political interference from the White House could have on the public confidence in a COVID-19 vaccine, and in the FDA itself. Marks said that the public conversation surrounding COVID-19 vaccines…
Learn More